Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Novacyt ( (FR:ALNOV) ).
Novacyt will publish its audited financial results for the year ended 31 December 2025 on 30 April 2026, and has scheduled an investor webinar hosted by CEO Lyn Rees and CFO Steve Gibson the same day to present the figures and take questions. The company is also directing investors to a new management video that explains the strategic rationale and planned use of proceeds for its recent acquisition of Australian distributor Southern Cross Diagnostics and the associated Preferential Subscription Rights issue, underlining its push to broaden distribution and strengthen its position in the life sciences and diagnostics markets across the Asia-Pacific region.
More about Novacyt
Novacyt S.A. is an international molecular diagnostics company focused on genomic medicine, developing, manufacturing and commercialising molecular assays and instrumentation. Its integrated technologies and services support end-to-end workflows from sample to result across human and animal health as well as environmental applications, with operations spanning Europe, North America, Asia and over 65 countries, including recent expansion into Australia.
For detailed information about ALNOV stock, go to TipRanks’ Stock Analysis page.